NasdaqGS:ACLXBiotechs
Arcellx (ACLX) Posts US$228.9m TTM Loss Testing Bullish Profitability Narratives
Arcellx (ACLX) closed FY 2025 with fourth quarter revenue of US$1.7 million and a basic EPS loss of US$1.00, alongside a quarterly net loss of US$58.1 million. On a trailing 12 month basis, revenue was US$22.3 million with a basic EPS loss of US$4.07 and a net loss of US$228.9 million. Over the past several quarters, the company has reported quarterly revenue ranging from US$26.0 million in Q3 2024 to US$1.7 million in Q4 2025, with basic EPS losses moving between US$0.48 and US$1.13 over the...